Mainz Biomed B.V.
MYNZ · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $894 | $895 | $530 | $577 |
| % Growth | -0.2% | 69% | -8.2% | – |
| Cost of Goods Sold | $319 | $386 | $348 | $400 |
| Gross Profit | $575 | $510 | $182 | $178 |
| % Margin | 64.3% | 56.9% | 34.4% | 30.8% |
| R&D Expenses | $5,839 | $9,590 | $3,660 | $467 |
| G&A Expenses | $8,080 | $13,418 | $17,832 | $8,454 |
| SG&A Expenses | $12,775 | $17,222 | $22,810 | $9,411 |
| Sales & Mktg Exp. | $4,695 | $3,803 | $4,979 | $958 |
| Other Operating Expenses | $656 | $342 | -$114 | -$321 |
| Operating Expenses | $19,270 | $27,154 | $26,357 | $9,557 |
| Operating Income | -$18,695 | -$26,645 | -$26,444 | -$9,725 |
| % Margin | -2,091.2% | -2,975.5% | -4,990.6% | -1,684.4% |
| Other Income/Exp. Net | -$2,955 | $349 | $57 | -$1,965 |
| Pre-Tax Income | -$21,651 | -$26,296 | -$26,387 | -$11,695 |
| Tax Expense | $0 | $0 | $0 | $377 |
| Net Income | -$21,651 | -$26,296 | -$26,453 | -$11,690 |
| % Margin | -2,421.8% | -2,936.5% | -4,992.2% | -2,024.8% |
| EPS | -22.36 | -1.62 | -1.87 | -1.67 |
| % Growth | -1,280.2% | 13.4% | -12% | – |
| EPS Diluted | -22.36 | -1.62 | -1.87 | -1.67 |
| Weighted Avg Shares Out | 968 | 16,242 | 14,157 | 7,211 |
| Weighted Avg Shares Out Dil | 968 | 16,242 | 14,157 | 7,211 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1,075 | $810 | $289 | $339 |
| Depreciation & Amortization | $1,017 | $1,035 | $459 | $70 |
| EBITDA | -$19,558 | -$25,011 | -$25,718 | -$11,281 |
| % Margin | -2,187.8% | -2,793.1% | -4,853.6% | -1,953.9% |